EPIX to Report First Quarter Results; Live Webcast and Conference Call Also Scheduled.Business Editors/Health/Medical Writers CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 15, 2004 Press Release Date and Time: Thursday, April 29, 2004, 4:00 pm EST EST electroshock therapy. EST abbr. electroshock therapy Conference Call Date and Time: Thursday, April 29, 2004, 4:30 pm EST EPIX EPIX Emergency Preparedness Information Exchange EPIX Enhanced Performance unIX EPIX European Property Stock Index Medical, Inc. (Nasdaq: EPIX), a developer of pharmaceuticals for magnetic resonance imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. (MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. ), today announced that it will release first quarter, 2004 financial results on Thursday, April 29, at 4:00 p.m. EST. A conference call is scheduled for 4:30 pm EST on Thursday, April 29. Dial-in number for the EPIX conference call is 888-464-7607. A recording of this call will be available from 6:00 pm (EST) on Thursday, April 29 through Friday, May 7, at 800-642-1687, reservation code 6802303. The call is being webcast by CCBN CCBN Central Coast Bancorp CCBN Charles County Business Network . The press release and the conference call webcast can also be found on the EPIX website at www.epixmed.com. An archived version will be available on the EPIX website two hours after the live webcast. EPIX Medical, based in Cambridge, MA, is a leading developer of targeted pharmaceuticals, currently specializing in MRI contrast agents for the diagnosis and clinical management of disease. The Company believes that MS-325, its lead product under development, has the potential to be an alternative to invasive X-ray angiography for diagnostic vascular imaging. On the strength of four successful MS-325 Phase III clinical trials, the Company submitted a New Drug Application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in December 2003 which was approved for filing in February 2004. Schering AG, the market leader in MRI contrast agents is the sales and marketing partner for MS-325. EPIX is also collaborating with Schering AG in the development of its second drug candidate, EP-2104R, for imaging blood clots using MRI, and in a research partnership to discover novel compounds for MRI. To receive the latest EPIX news and other corporate developments, please visit the EPIX Medical website at www.epixmed.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion